

**FORM 5**  
**QUARTERLY LISTING STATEMENT**

**For the Period ending October 31, 2019**

Name of CNSX Issuer: **CANNABIX TECHNOLOGIES INC.** (the "Issuer").

Trading Symbol: **BLO**

This Quarterly Listing Statement must be posted on or before the day on which the Issuer's unaudited interim financial statements are to be filed under the *Securities Act*, or, if no interim statements are required to be filed for the quarter, within 60 days of the end of the Issuer's first, second and third fiscal quarters. This statement is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CNSX Policies. If material information became known and was reported during the preceding quarter to which this statement relates, management is encouraged to also make reference in this statement to the material information, the news release date and the posting date on the CNSX.ca website.

**General Instructions**

- (a) Prepare this Quarterly Listing Statement using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the following items must be in narrative form. When the answer to any item is negative or not applicable to the Issuer, state it in a sentence. The title to each item must precede the answer.
- (b) The term "Issuer" includes the CNSX Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

There are three schedules which must be attached to this report as follows:

**SCHEDULE A: FINANCIAL STATEMENTS**

Please See Unaudited Interim Financial Statement for the most recent Quarter available under **CNSX FILINGS** at <http://www.cnsx.ca/CNSX/Securities/Technology/Cannabix-Technologies-Inc.aspx>

**SCHEDULE B: SUPPLEMENTARY INFORMATION**

The supplementary information set out below must be provided when not included in Schedule A.

**1. Related party transactions**

Please see Note 5 contained in the Unaudited Interim Financial Statements for the most recent Quarter available under **CNSX FILINGS** at <http://www.cnsx.ca/CNSX/Securities/Technology/Cannabix-Technologies-Inc.aspx>

Details:

- (a) As at October 31, 2019, the Company owed \$11,000 (2018 - \$10,000) to officers and directors of the Company which was included in accounts payable and accrued liabilities.

- (b) During the period ended October 31, 2019, the Company incurred consulting fees of \$37,500 (2018 - \$34,500) to the Chief Executive Officer of the Company.
- (c) During the period ended October 31, 2019, the Company incurred consulting fees of \$33,000 (2018 - \$30,000) to the Chief Financial Officer of the Company.
- (d) During the period ended October 31, 2019, the Company incurred consulting fees of \$42,000 (2018 - \$42,000) to a company controlled by the President of the Company.
- (e) During the period ended October 31, 2019, the Company incurred research and development costs of \$33,000 (2018 - \$30,000) to a director of the Company.
- (f) During the period ended October 31, 2019, the Company granted 1,845,000 (2018 - 1,350,000) stock options with a fair value of \$827,143 (2018 – \$1,689,534) to Directors and Officers.

**2. Summary of securities issued and options granted during the period.**

**(a) Summary of securities issued during the period**

Please see Note 6 contained in the Unaudited Interim Financial Statements for the most recent Quarter available under **CNSX FILINGS** at <http://www.cnsx.ca/CNSX/Securities/Technology/Cannabix-Technologies-Inc.aspx>.

Details:

Share transactions for the period ended October 31, 2019:

- (a) During the period ended October 31, 2019, the Company issued 1,100,000 common shares for proceeds of \$137,500 pursuant to the exercise of stock options. The fair value of the stock options exercised of \$136,012 was reallocated from contributed surplus to share capital.

Share issuance for the period ended October 31, 2018:

- (a) During the six-month period ended October 31, 2018, the Company issued 779,550 common shares for proceeds of \$664,810 pursuant to the exercise of share purchase warrants.

**(b) Summary of Options granted during the period**

During the period ended October 31, 2019, the Company granted 2,000,000 stock options exercisable at \$0.80 per share for a period of two years to consultants and five years to directors. The Company had 8,325,000 stock options outstanding as at October 31, 2019.

**3. Summary of securities as at the end of the reporting period.**

Provide the following information in tabular format as at the end of the reporting period:

**Authorized Capital stock:**

Unlimited common shares, no par value

	<u>Shares</u>
Issued and outstanding - common shares	
Balance, <b>October 31, 2019</b>	105,124,104

**Incentive Stock Options:**

During the period ended October 31, 2019, there were 8,325,000 options outstanding. As follows:

Number of Options	Exercise Price	Expiry Date
2,300,000	\$0.35	May 12, 2021
2,300,000	\$0.85	January 24, 2022
1,350,000	\$2.20	October 9, 2023
225,000	\$2.20	October 9, 2020
150,000	\$1.50	May 13, 2021
1,845,000	\$0.80	September 23, 2024
155,000	\$0.80	September 23, 2021

4. List the names of the directors and officers, with an indication of the position(s) held, as at the date this report is signed and filed.

Name of Director/Officer	Position with Issuer
Kal Malhi	President, Director
Raj Attariwala	Director
Bryan Loree	CFO, Director
Rav Mlait	CEO, Director
Thomas Clarke	Director

**SCHEDULE C: MANAGEMENT, DISCUSSION AND ANALYSIS**

Please See Management, Discussion and Analysis for the Quarter available under **CNSX FILINGS** at <http://www.cnsx.ca/CNSX/Securities/Technology/Cannabix-Technologies-Inc.aspx>

**Certificate of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Quarterly Listing Statement.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 5 Quarterly Listing Statement is true.

Dated December 9, 2019

**Rav Mlait** \_\_\_\_\_  
Name of Director/Senior Officer

*"Rav Mlait"* \_\_\_\_\_  
Signature

CEO \_\_\_\_\_  
Official Capacity

<b>Issuer Details</b>		
Name of Issuer <b>Cannabix Technologies Inc.</b>	For Quarter Ended <b>October 31, 2019</b>	Date of Report <b>2019/12/09</b>
Issuer Address <b>501 - 3292 Production Way</b>		
City/Province/Postal Code <b>Burnaby, BC, V5A 4R4</b>	Issuer Fax No. <b>604-676-2767</b>	Issuer Telephone No. <b>604-551-7831</b>
Contact Name <b>Rav Mlait</b>	Contact Position <b>CEO</b>	Contact Telephone No. <b>604-551- 7831</b>
<b>info@cannabixtechnologies.com</b>	<b>www. cannabixtechnologies.com</b>	